Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
Kidney Disease, Diabetic Nephropathy, Glomerulonephritis
About this trial
This is an interventional prevention trial for Kidney Disease focused on measuring spironolactone, proteinuria, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, renin angiotensin aldosterone system, aldosterone
Eligibility Criteria
Inclusion Criteria: Proteinuria more than 1.5 g/day On ACEI for more than 6 months Serum creatinine less than 200 micromol/L with less than 20% variability in the preceeding 3 months Creatinine clearance more than 30 ml/min, with less than 20% variability in the preceeding 3 months Exclusion Criteria: Serum potassium level more than 5 mmol/L Treatment with corticosteroids, NSAID or immunosuppressant medication Acute myocardial infarction or cerebrovascular accident in the previous 6 months Severe uncontrolled hypertension (diastolic > 115 mmHg or systolic BP [blood pressure] > 220 mmHg) Evidence or suspicion of renovascular disease, obstructive uropathy, collagen disease, cancer, drug or alcohol abuse, pregnancy, or breast feeding and ineffective contraception
Sites / Locations
- Department of Nephrology, The Royal Melbourne Hospital